Skip to main content
Clinical Trials/CTRI/2014/03/004494
CTRI/2014/03/004494Active, not recruiting未知

Assessment of the effectiveness of prophylactic replacement of lower than ââ?¬Ë?standardââ?¬â?¢ doses of clotting factor concentrates in children with severe hemophilia A - MUSFIH-PRO

BAYER AWARD0 sites30 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Severe hemophilia, defined as factor assay showing <1% activity, between 3-7 years of age
  • 2. No single joint should have an HJHS score of more than 5.
  • 3. Not have detectable inhibitors by Bethesda assay ( <0.6 BU) at recruitment
  • 4. Be willing to come for evaluation once in 9-15 months for at least 2 (?4) years. (in case
  • the study is extended)

Exclusion Criteria

  • PATIENTS WITH DOCUMENTED INHIBITORS.
  • NOT WILLING TO COME FOR FOLLOW UP FOR LONG TERM (ATLEAST 4 YEARS)

Investigators

Sponsor
BAYER AWARD

Similar Trials

ow dose Prophylaxis study in children with... | Clinical Trial